Contents

Scientific Abstracts

Welcome Address
EULAR 2022 Abstracts Reviewers

Oral Presentations

OP0001
OP0002
OP0003
OP0004
OP0006
OP0008–OP0015
OP0016–OP0023
OP0024–OP0031
OP0032–OP0039
OP0042–OP0049
OP0050–OP0057
OP0058–OP0065
OP0066–OP0073
OP0074–OP0081
OP0082–OP0089
OP0090–OP0097
OP0098
OP0099
OP0100–OP0107
OP0108–OP0115
OP0124–OP0131
OP0132–OP0139
OP0140–OP0147
OP0148–OP0155
OP0156–OP0163
OP0164–OP0171
OP0172–OP0179
OP0180–OP0187
OP0188
OP0190
OP0191
OP0192
OP0193
OP0194
OP0195–OP0196
OP0197
OP0199
OP0215–OP0222
OP0223–OP0230
OP0231–OP0238
OP0239–OP0246
OP0247–OP0254
OP0255–OP0262
OP0263–OP0270
OP0271–OP0278
OP0279–OP0286
OP0287–OP0294
OP0297
OP0300

Addressing the effect of Placebo, Nocebo and Contextual factors in RMDs
Bench to Bedside: The complement system in rheumatic diseases
Breaking the barriers: gut, lung and skin in arthritis pathogenesis
Does AI really help me diagnosing RMDs?
Is gender sufficiently studied in RMDs?
Plenary Abstract Session
AxSpA drug treatment: new and old drugs
Clinical aspects in Psoriatic Arthritis
From risk assessment to societal outcomes
Infection-related and other orphan rheumatic disorders
Managing chronic pain in RMDs
Modern biological treatment in RA
Adaptive immunity (T cells and B cells) in rheumatic diseases / Innate immunity in rheumatic diseases
Rheumatoid arthritis - aetiology, pathogenesis and animal models
Rheumatoid arthritis - prognosis and prediction
The Yin and Yang of scleroderma and vasculitis
Microbiome and SpA
The role of the synovial microenvironment during onset and progression of arthritis
Exploring the origin of inflammation in spondyloarthritides
From gene to function: genetic basis of rheumatic diseases
Pregnancy outcomes in rheumatic diseases
RA: Clinical aspects and comorbidities - I
Remission, flares and predictive factors in SLE, Sjogren and anti-phospholipid syndrome
Spondyloarthritis in practice: imaging, outcome assessment and comorbidities
The treatment and outcome of scleroderma
Translational and Clinical Research in Crystal Arthritis
Vaccination against SARS-CoV-2
Vessels glowing in the dark
Active Ageing: new perspectives for RMD patients?
Modern technology for precision medicine
Rheumatology in Europe
Vaccination in rheumatic diseases with lessons from COVID
sJIA vs AOSD: Two names one disease? What have we learnt so far?
Autoinflammation over the course of a lifetime
Challenges of fibromyalgia
Long-COVID
Strengths and weaknesses of experimental models: Moving from animals to human clinical trials
Improving outcomes for children with JIA
New developments in OA
Novel etiopathogenic aspects in SLE and Sjögren’s syndrome
Osteoporosis
Outcome of COVID-19 in Rheumatic Diseases
Emerging treatment strategies in PsA
RA treatment: modern strategies and new molecules
RA: Clinical aspects and comorbidities - II
Recent novelties in SLE/Sjogren and APS?
The early bird gets the worm
Sjogren syndrome: from biopsy to lymphoma
Crystal arthritis
Rheumatology across boundaries ................................................................. 200
How to review a manuscript ........................................................................ 202
Interstitial lung disease in RMDs ................................................................. 203
New lessons for rheumatology in genomics medicine ................................. 204

Late breaking abstracts

Challenges in measuring and predicting RMDs ........................................... 212
Challenging cases to make you think .......................................................... 220
Chronic pain - Mechanisms, epidemiology, and treatment ......................... 224
Genomics, functional genomics and genetic basis of inflammatory arthritis .................................................................................................................. 230
Immunity in Rheumatic Diseases ................................................................. 240
Lung involvement in Rheumatic Diseases .................................................... 247
New therapeutic avenues in psoriatic arthritis ............................................ 253
Pathogenesis of SLE, Sjögren's and antiphospholipid syndrome ................ 267
Rheumatoid arthritis – prognosis, predictors and outcome ......................... 274
Systemic lupus erythematosus, Sjögren's syndrome and anti-phospholipid syndrome........................................................................................................ 282
Through the looking glass .......................................................................... 287
Biomarkers in pathogenesis, monitoring and treatment of rheumatic diseases .................................................................................................................. 294
Clinical aspect of spondyloarthritis .............................................................. 300
Health services research: scoping the landscape .......................................... 305
Improving our care and understanding of paediatric RMDs ....................... 311
New insights into the associations of outcomes and biomarkers in OA ......... 317
New options in SLE-Sjögren and APS ......................................................... 323
Outcome of COVID-19 in patients with rheumatic diseases ....................... 330
RA comorbidities ....................................................................................... 338
Recent advances in orphan rheumatic diseases .......................................... 343
Remodelling in OA .................................................................................... 349
Rheumatoid arthritis: JAKi and beyond ..................................................... 353
Small vessels on fire ................................................................................... 361
Vaccination against SARS-CoV-2 ............................................................... 367
Achy-Breaky vessels .................................................................................... 374
Advances in Crystal Arthritis ..................................................................... 381
All you want to know about bDMARDs in RA. ............................................ 387
AxSpA: About treatments and outcomes .................................................... 394
Clinical aspects in Psoriatic Arthritis .......................................................... 403
Mortality, Co-morbidity and disease burden ................................................. 409
New data on pathophysiology of spondyloarthritis including psoriatic arthritis ................................................................................................. 414
New insights into the management of JIA .................................................... 419
Novel molecular regulators of bone turnover ............................................... 426
Systemic Lupus Erythematosus: monitoring and management ................... 434
Telemedicine what does it tell us ............................................................... 440
What's new in scleroderma and myositis? .................................................... 445

POSTERS only

Genomics, genetic basis of disease and functional genomics .......................... 453
Adaptive immunity (T cells and B cells) in rheumatic diseases .................... 455
Innate immunity in rheumatic diseases ........................................................ 458
Osteo arthritis, aetiology, pathology and animal models ............................. 459
Rheumatoid arthritis - aetiology, pathogenesis and animal models ............. 460
Spondyloarthritis - aetiology, pathogenesis and animal models .................. 479
SLE, Sjögren's and APS - aetiology, pathogenesis and animal models .......... 480
Systemic sclerosis, myositis and related syndromes - aetiology, pathogenesis and animal models .................................................................................. 488
Vasculitis - aetiology, pathogenesis and animal models ............................... 500
Basic and translational science in paediatric rheumatology .......................... 502
<table>
<thead>
<tr>
<th>Publication Only</th>
</tr>
</thead>
<tbody>
<tr>
<td>AB0001–AB0016</td>
</tr>
<tr>
<td>AB0017–AB0035</td>
</tr>
<tr>
<td>AB0036–AB0044</td>
</tr>
<tr>
<td>AB0045–AB0053</td>
</tr>
<tr>
<td>AB0054–AB0055</td>
</tr>
<tr>
<td>AB0056–AB0103</td>
</tr>
<tr>
<td>AB0104–AB0142</td>
</tr>
<tr>
<td>AB0143–AB0155</td>
</tr>
<tr>
<td>AB0236–AB0329</td>
</tr>
<tr>
<td>AB0330–AB0381</td>
</tr>
<tr>
<td>AB0382–AB0421</td>
</tr>
<tr>
<td>AB0422–AB0448</td>
</tr>
<tr>
<td>AB0449–AB0575</td>
</tr>
<tr>
<td>AB0576–AB0609</td>
</tr>
<tr>
<td>AB0610–AB0643</td>
</tr>
<tr>
<td>AB0644–AB0749</td>
</tr>
<tr>
<td>AB0750–AB0780</td>
</tr>
<tr>
<td>AB0781–AB0878</td>
</tr>
<tr>
<td>AB0879–AB0921</td>
</tr>
<tr>
<td>AB0922–AB0968</td>
</tr>
<tr>
<td>AB0967–AB1006</td>
</tr>
<tr>
<td>AB1007–AB1034</td>
</tr>
<tr>
<td>AB1035–AB1069</td>
</tr>
<tr>
<td>AB1070–AB1080</td>
</tr>
<tr>
<td>AB1081–AB1193</td>
</tr>
</tbody>
</table>

POS0498: Basic and translational pain science ........................................ 503
POS0499–POS0578: Rheumatoid arthritis - prognosis, predictors and outcome ........................................ 504
POS0579–POS0635: Rheumatoid arthritis - comorbidity and clinical aspects ........................................ 556
POS0636–POS0662: Rheumatoid arthritis - biological DMARDs ........................................ 587
POS0663–POS0704: Rheumatoid arthritis - non biologic treatment and small molecules ........................................ 604
POS0705–POS0721: SLE, Sjögren's and APS - treatment ........................................ 633
POS0722–POS0790: SLE, Sjögren's and APS - clinical aspects (other than treatment) ........................................ 644
POS0791–POS0821: Vasculitis – large vessel vasculitis ........................................ 683
POS0822–POS0838: Vasculitis – small vessel vasculitis ........................................ 702
POS0839–POS0929: Scleroderma, myositis and related syndromes ........................................ 711
POS0930–POS0954: Spondyloarthritis – treatment ........................................ 765
POS0955–POS1012: Spondyloarthritides - clinical aspects (other than treatment) ........................................ 783
POS1013–POS1062: Psoriatic arthritis – treatment ........................................ 815
POS1063–POS1104: Psoriatic arthritis - clinical aspects (other than treatment) ........................................ 854
POS1105–POS1138: Osteoarthritis ........................................ 881
POS1139–POS1153: Osteoporosis ........................................ 898
POS1154–POS1177: Crystal diseases, metabolic bone diseases other than osteoporosis ........................................ 905
POS1178–POS1189: COVID-19 ........................................ 917
POS1190–POS1286: Pain in rheumatic diseases, including fibromyalgia ........................................ 981
POS1287–POS1288: Spine, mechanical musculoskeletal problems, local soft tissue disorders ........................................ 982
POS1289–POS1292: Paediatric rheumatology ........................................ 983
POS1293–POS1326: Other orphan diseases ........................................ 1001
POS1327–POS1379: Diagnostics and imaging procedures ........................................ 1030
POS1380–POS1401: Public health, health services research, and health economics ........................................ 1041
POS1402–POS1406: Epidemiology, risk factors for disease or disease progression ........................................ 1045
POS1407–POS1447: Validation of outcome measures and biomarkers ........................................ 1069
POS1448–POS1451: Rehabilitation ........................................ 1071
POS1452–POS1455: Education ........................................ 1072
POS1456–POS1460: Educational cases ........................................ 1075
POS1461–POS1469: Genomics, genetic basis of disease and functional genomics ........................................ 1136
POS1470–POS1500: Adaptive immunity (T cells and B cells) in rheumatic diseases ........................................ 1143
POS1501–POS1530: Innate immunity in rheumatic diseases ........................................ 1153
POS1531–POS1550: Osteoarthritis, etiology, pathology and animal models ........................................ 1157
POS1551–POS1615: Bone diseases, etiology, pathology and animal models ........................................ 1161
POS1616–POS1630: Rheumatoid arthritis - etiology, pathogenesis and animal models ........................................ 1162
POS1631–POS1680: Spondyloarthritides - etiology, pathogenesis and animal models ........................................ 1183
POS1681–POS1700: SLE, Sjögren's and APS - etiology, pathogenesis and animal models ........................................ 1188
POS1701–POS1720: Systemic sclerosis, myositis and related syndromes - etiology, pathogenesis and animal models ........................................ 1193
POS1721–POS1740: Vasculitis - etiology, pathogenesis and animal models ........................................ 1201
POS1741–POS1760: Basic and translational science in paediatric rheumatology ........................................ 1207
POS1761–POS1800: Basic and translational pain science ........................................ 1208
POS1801–POS1820: Rheumatoid arthritis - prognosis, predictors and outcome ........................................ 1209
POS1821–POS1840: Rheumatoid arthritis - comorbidity and clinical aspects ........................................ 1246
POS1841–POS1860: Rheumatoid arthritis - biological DMARDs ........................................ 1289
POS1861–POS1880: Rheumatoid arthritis - non biologic treatment and small molecules ........................................ 1318
POS1881–POS1900: SLE, Sjögren's and APS - treatment ........................................ 1339
POS1901–POS1920: SLE, Sjögren's and APS - clinical aspects (other than treatment) ........................................ 1353
POS1921–POS1940: Vasculitis – large vessel vasculitis ........................................ 1414
POS1941–POS1960: Vasculitis – small vessel vasculitis ........................................ 1430
POS1961–POS2000: Scleroderma, myositis and related syndromes ........................................ 1449
POS2001–POS2040: Spondyloarthritides – treatment ........................................ 1500
POS2041–POS2060: Spondyloarthritides - clinical aspects (other than treatment) ........................................ 1517
POS2061–POS2080: Psoriatic arthritis – treatment ........................................ 1562
POS2081–POS2100: Psoriatic arthritis - clinical aspects (other than treatment) ........................................ 1590
POS2101–POS2140: Osteoarthritis ........................................ 1611
POS2141–POS2160: Osteoporosis ........................................ 1627
POS2161–POS2180: Crystal diseases, metabolic bone diseases other than osteoporosis ........................................ 1641
POS2181–POS2200: Infection-related rheumatic diseases ........................................ 1655
POS2201–POS2240: COVID-19 ........................................ 1660
Health Professionals in Rheumatology Abstracts

Oral Presentations
OP0007-HPR “Not another pill!” Integrative pain management approaches ........................................ 4
OP0116-HPR–OP0123-HPR HPR: From prevention to management ........................................... 76
OP0198-HPR How do we overcome the research-to-practice gap? Implementation of evidence into the rheumatology practice ........................................... 131
OP0207-HPR–OP0214-HPR HPR interventions on the spotlight ................................................ 136
OP0295-HPR Lifestyle and Disease activity in inflammatory arthritis ....................................... 196
OP0296-HPR Complexity of care in RMD: intersection between health and social care ............... 197
OP0299-HPR Facilitating work participation – why and how? .................................................... 198
OP0301-HPR Digital-Health and Tailored Interventions for Improving Patients’ Adherence: Opportunities and Challenges ........................................... 200
OP0308-HPR Keeping the “Dark clouds” away: Psychological distress and RMDs ...................... 204

Poster Tours
POS0040-HPR–POS0049-HPR HPR Poster Tour: Moving together towards person-centred care ...... 235

POSTERS only
POS1470-HPR–POS1492-HPR HPR Measuring health (development and measurement properties of PROs, tests, devices) .................................................. 1081
POS1493-HPR–POS1495-HPR HPR Epidemiology and public health (including prevention) ...... 1092
POS1496-HPR–POS1510-HPR HPR Interventions (educational, physical, social and psychological) .................................................................................... 1093
POS1511-HPR–POS1543-HPR HPR Patients’ perspectives, functioning and health (descriptive: qualitative or quantitative) .............................................. 1101
POS1544-HPR–POS1553-HPR HPR Service developments, innovation and economics in healthcare 1117
POS1554-HPR–POS1559-HPR HPR Professional education, training and competencies .......... 1122
POS1560-HPR–POS1561-HPR HPR Interdisciplinary research .................................................... 1126

Publication Only
AB1523-HPR–AB1533-HPR HPR Measuring health (development and measurement properties of PROs, tests, devices) .................................................. 1864
AB1534-HPR HPR Epidemiology and public health (including prevention) .................................... 1869
AB1535-HPR–AB1543-HPR HPR Interventions (educational, physical, social and psychological) .................................................................................... 1869
AB1544-HPR–AB1554-HPR HPR Patients’ perspectives, functioning and health (descriptive: qualitative or quantitative) .............................................. 1873
AB1555-HPR–AB1562-HPR HPR Service developments, innovation and economics in healthcare 1878
AB1563-HPR–AB1566-HPR HPR Professional education, training and competencies .......... 1881
AB1567-HPR HPR Interdisciplinary research .................................................... 1883

People with Arthritis and Rheumatism in Europe Abstracts

Oral Presentations
OP0005-PARE How to maintain your quality of life after an RMD diagnosis ................................... 3
OP0040-PARE–OP0041-PARE In dialogue with the expert: axSpA and Sjogren’s syndrome .......... 28
OP0189-PARE From childhood to adulthood - growing up with an RMD ..................................... 125
OP0200-PARE–OP0206-PARE From abstract to concrete – the variety of activities of PARE organizations ........................................... 132
OP0298-PARE Enhancing research through patient involvement ................................................ 198
<table>
<thead>
<tr>
<th><strong>Poster Tours</strong></th>
<th><strong>Poster Tours</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>POS0083-PARE–POS0091-PARE</td>
<td>PARE Poster Tour 1</td>
</tr>
<tr>
<td>POS0352-PARE–POS0361-PARE</td>
<td>PARE Poster Tour 2</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>POSTERS only</strong></th>
<th><strong>POSTERS only</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>POS1562-PARE–POS1568-PARE</td>
<td>Patient information and education</td>
</tr>
<tr>
<td>POS1569-PARE</td>
<td>Building patient led organisations</td>
</tr>
<tr>
<td>POS1570-PARE</td>
<td>Arthritis research</td>
</tr>
<tr>
<td>POS1571-PARE–POS1573-PARE</td>
<td>Innovations in arthritis health care</td>
</tr>
<tr>
<td>POS1574-PARE</td>
<td>Psychosocial support</td>
</tr>
<tr>
<td>POS1575-PARE</td>
<td>Work and rehabilitation</td>
</tr>
<tr>
<td>POS1576-PARE–POS1579-PARE</td>
<td>Best practice campaigning</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Publication Only</strong></th>
<th><strong>Publication Only</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>AB1568-PARE–AB1581-PARE</td>
<td>Patient information and education</td>
</tr>
<tr>
<td>AB1582-PARE</td>
<td>Building patient led organisations</td>
</tr>
<tr>
<td>AB1583-PARE–AB1585-PARE</td>
<td>Arthritis research</td>
</tr>
<tr>
<td>AB1586-PARE</td>
<td>Innovations in arthritis health care</td>
</tr>
<tr>
<td>AB1587-PARE</td>
<td>Work and rehabilitation</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Author Index</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>1893</td>
</tr>
</tbody>
</table>